Kopran Ltd
NSE:KOPRAN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
124.29
221.16
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Kopran Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Kopran Ltd
NSE:KOPRAN
|
6.2B INR |
3%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
31%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
507.7B USD |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
253.1B CHF |
15%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209B GBP |
16%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
206.8B CHF |
26%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
249.9B USD |
30%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
33%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
209B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
16%
|
Kopran Ltd
Glance View
Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing and supplying international formulations (Finished Dosage Form) and active pharmaceutical ingredients (APIs). Its formulation business unit manufactures oral solid dosages and dry powder formulations for both penicillin and non-penicillin-based drugs. Its APIs business unit offers Sterile Cephalosporins and Carbapenems. The company also offers Macrolide, Antibacterial, Anticonvulsant, and Cardiovascular range of drugs. Its product offering includes antibiotics, cardiovascular, antidiabetic, gastrointestinal, pain management, drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, and anthelmintics. Its antibiotics brands include AMPIK 250 / 500, AMPIK SYRUP, and AMYN - 250 / 500. Its cardiovascular brands include CARDIOTEN - 25 / 50 / 100, CADITONE - 3.125 / 6.25 / 12.5 / 25 and KLODIP - 5 / 10.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Kopran Ltd's most recent financial statements, the company has Net Margin of 3%.